MedTrace Logo

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

NCT00851864 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2013-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Tinzaparin

LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily. Treatment will be done for the duration of the pregnancy.

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Paul Gibson, M.D. FRCPC · University of Calgary

  • Kendra Newell, M.D. · University of Calgary

  • David Sam, M.D. FRCPC · University of Calgary

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-10-31
Completion
2011-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851864 on ClinicalTrials.gov